IL6 and neoplasm: Cancer-associated muscle loss primarily results from systemic inflammatory responses induced by host-tumor interactions (4), as inflammatory cytokines derived from tumor cells such as IL-6 and TNF-α can impair the differentiation of skeletal muscle cells (5), interfere with insulin signaling, and thereby drive more severe insulin resistance and the degradation of muscle tissue (6).